Metagen Therapeutics, Inc.
PrivateLast Round
Series B
Extension
Sep 25, 2026
Total Funding Raised
$53.61M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Metagen Therapeutics, Inc. operates in Healthcare & Life Sciences and is based in Tsuruoka. Its latest recorded funding round was a Series B Extension round in September 2026.
Metagen Therapeutics, Inc. is a biotechnology company that advances medicine and drug discovery based on human gut microbiome research.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Metagen Therapeutics, Inc. Comparables
Compare Metagen Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BiomeBank | 83% | |
| MRM Health | 82% | |
| EnteroBiotix | 82% |
For institutional investors. Book with your work email.
Metagen Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Sep 25, 2026 | ||||
| Series B | Feb 25, 2026 | ||||
| Series B | Sep 8, 2025 | ||||
| Series A | Jun 15, 2023 | ||||
| Pre Seed | Jun 30, 2022 | ||||
Seed | Mar 17, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Metagen Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| JAFCO Group Co., Ltd. | Seed, Series A, Pre Seed, Series B |
| Tokai Tokyo Investment Co., Ltd. | Series B |
| Keio Innovation Initiative | Seed, Series A, Pre Seed, Series B |
| Mizuho Capital | Series A, Series B |
| Arcus Investment | Series B |
| 日本ベンチャーキャピタル株式会社 | Series A, Series B |
| Dentsu Ventures | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 25, 2026
$1.9M round led by GLIN Impact Capital.
- Jul 27, 2026
Monthly visitors increased 38% MoM, reaching 6.1K.
For institutional investors. Book with your work email.
Metagen Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Metagen Therapeutics, Inc.'s valuation, stock price, and market status.
Is Metagen Therapeutics, Inc. a public or private company?
Metagen Therapeutics, Inc. is a private company.
What is the current stock price of Metagen Therapeutics, Inc.?
Metagen Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Metagen Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Metagen Therapeutics, Inc. worth (valuation)?
Valuation information for Metagen Therapeutics, Inc. is not publicly available.
Can I buy Metagen Therapeutics, Inc. stock?
Metagen Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Metagen Therapeutics, Inc.'s last funding round?
Metagen Therapeutics, Inc.'s most recent funding round was Series B Extension on September 25, 2026.
Who are the main investors in Metagen Therapeutics, Inc.?
Key investors in Metagen Therapeutics, Inc. include Fast Track Initiative.
Will Metagen Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Metagen Therapeutics, Inc..
How can I track Metagen Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Metagen Therapeutics, Inc.'s shares on secondary markets.